197 related articles for article (PubMed ID: 37830334)
1. Asundexian: an oral small molecule factor XIa inhibitor for the treatment of thrombotic disorders.
D'Allesandro N; Cave B; Hough A
Future Cardiol; 2023 Aug; 19(10):477-486. PubMed ID: 37830334
[TBL] [Abstract][Full Text] [Related]
2. Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study.
Piccini JP; Caso V; Connolly SJ; Fox KAA; Oldgren J; Jones WS; Gorog DA; Durdil V; Viethen T; Neumann C; Mundl H; Patel MR;
Lancet; 2022 Apr; 399(10333):1383-1390. PubMed ID: 35385695
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological profile of asundexian, a novel, orally bioavailable inhibitor of factor XIa.
Heitmeier S; Visser M; Tersteegen A; Dietze-Torres J; Glunz J; Gerdes C; Laux V; Stampfuss J; Roehrig S
J Thromb Haemost; 2022 Jun; 20(6):1400-1411. PubMed ID: 35289054
[TBL] [Abstract][Full Text] [Related]
4. A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes After Acute Myocardial Infarction.
Rao SV; Kirsch B; Bhatt DL; Budaj A; Coppolecchia R; Eikelboom J; James SK; Jones WS; Merkely B; Keller L; Hermanides RS; Campo G; Ferreiro JL; Shibasaki T; Mundl H; Alexander JH;
Circulation; 2022 Oct; 146(16):1196-1206. PubMed ID: 36030390
[TBL] [Abstract][Full Text] [Related]
5. A Review of FXIa Inhibition as a Novel Target for Anticoagulation.
Koulas I; Spyropoulos AC
Hamostaseologie; 2023 Feb; 43(1):28-36. PubMed ID: 36807817
[TBL] [Abstract][Full Text] [Related]
6. Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial.
Shoamanesh A; Mundl H; Smith EE; Masjuan J; Milanov I; Hirano T; Agafina A; Campbell B; Caso V; Mas JL; Dong Q; Turcani P; Christensen H; Ferro JM; Veltkamp R; Mikulik R; De Marchis GM; Robinson T; Lemmens R; Stepien A; Greisenegger S; Roine R; Csiba L; Khatri P; Coutinho J; Lindgren AG; Demchuk AM; Colorado P; Kirsch B; Neumann C; Heenan L; Xu L; Connolly SJ; Hart RG;
Lancet; 2022 Sep; 400(10357):997-1007. PubMed ID: 36063821
[TBL] [Abstract][Full Text] [Related]
7. Effect of the Factor XIa Inhibitor Asundexian According to Baseline Infarct Pattern and on MRI Covert Infarct Outcomes.
Smith EE; Shoamanesh A; Xu L; Heenan L; Saad F; Colorado P; Chen CH; Lemmens R; De Marchis GM; Caso V; Masjuan J; Hirano T; Milanov I; Campbell BCV; Mas JL; Connolly SJ; Mundl H; Hart RG;
Stroke; 2024 Feb; 55(2):392-402. PubMed ID: 38174569
[TBL] [Abstract][Full Text] [Related]
8. Pharmacology and Clinical Development of Factor XI Inhibitors.
Greco A; Laudani C; Spagnolo M; Agnello F; Faro DC; Finocchiaro S; Legnazzi M; Mauro MS; Mazzone PM; Occhipinti G; Rochira C; Scalia L; Capodanno D
Circulation; 2023 Mar; 147(11):897-913. PubMed ID: 36913497
[TBL] [Abstract][Full Text] [Related]
9. Determination of the Potential Clinical Benefits of Small Molecule Factor XIa Inhibitors in Arterial Thrombosis.
Wichaiyo S; Parichatikanond W; Visansirikul S; Saengklub N; Rattanavipanon W
ACS Pharmacol Transl Sci; 2023 Jul; 6(7):970-981. PubMed ID: 37470020
[TBL] [Abstract][Full Text] [Related]
10. Three-month risk-benefit profile of anticoagulation after stroke with atrial fibrillation: The SAMURAI-Nonvalvular Atrial Fibrillation (NVAF) study.
Arihiro S; Todo K; Koga M; Furui E; Kinoshita N; Kimura K; Yamagami H; Terasaki T; Yoshimura S; Shiokawa Y; Kamiyama K; Takizawa S; Okuda S; Okada Y; Nagakane Y; Kameda T; Hasegawa Y; Shibuya S; Ito Y; Nakashima T; Takamatsu K; Nishiyama K; Matsuki T; Homma K; Takasugi J; Tokunaga K; Sato S; Kario K; Kitazono T; Toyoda K;
Int J Stroke; 2016 Jul; 11(5):565-74. PubMed ID: 26927811
[TBL] [Abstract][Full Text] [Related]
11. Development of new anticoagulant in 2023: Prime time for anti-factor XI and XIa inhibitors.
Bentounes NK; Melicine S; Martin AC; Smadja DM; Gendron N
J Med Vasc; 2023 Apr; 48(2):69-80. PubMed ID: 37422330
[TBL] [Abstract][Full Text] [Related]
12. Cerebral microbleeds and asundexian in non-cardioembolic ischemic stroke: Secondary analyses of the PACIFIC-STROKE randomized trial.
Balali P; Hart RG; Smith EE; Saad F; Colorado P; Lemmens R; De Marchis GM; Caso V; Xu L; Heenan L; Connolly SJ; Mundl H; Shoamanesh A
Int J Stroke; 2024 Jun; 19(5):526-535. PubMed ID: 37950392
[TBL] [Abstract][Full Text] [Related]
13. Use of novel oral anticoagulants for patients with atrial fibrillation: systematic review and clinical implications.
Albert NM
Heart Lung; 2014; 43(1):48-59. PubMed ID: 24373340
[TBL] [Abstract][Full Text] [Related]
14. Commentary on "Pharmacological profile of asundexian, a novel, orally bioavailable inhibitor of factor XIa": Small molecule factor XIa inhibitor asundexian allows for safer anticoagulation.
Mailer RK; Renné T
J Thromb Haemost; 2022 Jun; 20(6):1309-1311. PubMed ID: 35596514
[No Abstract] [Full Text] [Related]
15. New pharmacotherapeutic options for oral anticoagulant treatment in atrial fibrillation patients aged 65 and older: factor XIa inhibitors and beyond.
Santostasi G; Denas G; Pengo V
Expert Opin Pharmacother; 2023; 24(12):1335-1347. PubMed ID: 37243619
[TBL] [Abstract][Full Text] [Related]
16. Thrombosis, Bleeding, and the Promise of Factor XI(a) Inhibition.
Andreotti F; Massetti M; Montalescot G
J Am Coll Cardiol; 2024 Feb; 83(6):679-681. PubMed ID: 38325993
[No Abstract] [Full Text] [Related]
17. Clinical Evaluation of Factor XIa Inhibitor Drugs: JACC Review Topic of the Week.
Harrington J; Piccini JP; Alexander JH; Granger CB; Patel MR
J Am Coll Cardiol; 2023 Feb; 81(8):771-779. PubMed ID: 36813377
[TBL] [Abstract][Full Text] [Related]
18. Design and Preclinical Characterization Program toward Asundexian (BAY 2433334), an Oral Factor XIa Inhibitor for the Prevention and Treatment of Thromboembolic Disorders.
Roehrig S; Ackerstaff J; Jiménez Núñez E; Teller H; Ellerbrock P; Meier K; Heitmeier S; Tersteegen A; Stampfuss J; Lang D; Schlemmer KH; Schaefer M; Gericke KM; Kinzel T; Meibom D; Schmidt M; Gerdes C; Follmann M; Hillisch A
J Med Chem; 2023 Sep; 66(17):12203-12224. PubMed ID: 37669040
[TBL] [Abstract][Full Text] [Related]
19. Drugs in phase I and II clinical development for the prevention of stroke in patients with atrial fibrillation.
Bentley R; Hardy LJ; Scott LJ; Sharma P; Philippou H; Lip GYH
Expert Opin Investig Drugs; 2021 Oct; 30(10):1057-1069. PubMed ID: 33682570
[TBL] [Abstract][Full Text] [Related]
20. Nonvitamin-K-antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and previous stroke or transient ischemic attack: An updated systematic review and meta-analysis of randomized controlled trials.
Ntaios G; Papavasileiou V; Diener HC; Makaritsis K; Michel P
Int J Stroke; 2017 Aug; 12(6):589-596. PubMed ID: 28730948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
